Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

THE WOODLANDS, Texas, Dec. 14, 2010 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA).  LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues. The trial was the first test of this new anti-inflammatory mechanism of action in patients and was designed to obtain safety and tolerability information and signals of efficacy.  

Results from the 12-week, randomized, double-blind, placebo-controlled study in 208 patients with RA demonstrated that all three doses tested, 70 mg, 110 mg, and 150 mg given once per day, were well tolerated over the 12-week treatment period.  Taken together, the data also suggested that patients treated with 150 mg once daily of LX2931 showed an improvement in the primary efficacy endpoint, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12 (60% versus 49% for placebo).  Patients treated with 70 mg or 110 mg once daily did not indicate improvement in the ACR20 at week 12 (44% and 41% response rates, respectively) relative to placebo. Adverse events for all three LX2931 dose groups were predominantly mild-to-moderate, with frequencies similar to the placebo group.

"We believe the preliminary signal of efficacy and the favorable safety profile observed in this trial supports further study
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
... Mass., May 7, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that its ... the scientific sessions and during a private academic ... Society,s 33rd Annual Scientific Sessions, May 9-12 in ...
Cached Medicine Technology:Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 2Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 3
(Date:9/19/2014)... biosensor made from the wonder material graphene has been ... of developing cancer. , The biosensor has been ... than bioassay tests currently in use, and was able ... up the possibility of a rapid, point-of-care diagnostic tool ... 19 September, in IOP Publishing,s journal 2D Materials ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... integral part of the medical imaging market, are engineered ... technology developments over the past three decades have expanded ... From barium and iodine based agents used for over ... nanoparticles and radiopharmaceuticals, imaging agents have witnessed sea changes, ...
(Date:9/19/2014)... 2014 The Nordic ... style of eating, is making its way ... Doc’s medical weight loss programs, ... good food which leads to improved health. ... patients to understand how diet can impact ...
(Date:9/19/2014)... Boston, MA (PRWEB) September 19, 2014 ... in the freight trucking industry increased their sales by ... like this from the trucking industry can be used ... is doing as a whole. This data has been ... to other forms of freight transportation. Other non-trucking data ...
(Date:9/19/2014)... September 19, 2014 Activz Whole-Food Nutrition ... Smoothie product, a new whole-food produce powder smoothie, ... Baltimore, MD. Activz Greens Smoothie is a ... one convenient – and absolutely delicious —Greens Smoothie. Details ... Baltimore, MD. , The new ...
Breaking Medicine News(10 mins):Health News:Graphene sensor tracks down cancer biomarkers 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3
... back in 2002, at the San Francisco's 2002 Gay Pride, ... campaign to popularize syphilis testing. ,In the above ... introduced to Gayville, encouraging the many hundreds of homo whores ... big-S. (Syphilis) ,Although many were not happy with ...
... Fresh bird flu outbreaks reported from Vietnam and South ... Ministry is fully stocked and ready to deal with ... ,The Ministry has a stock of 2.5 ... birds and 475,000 doses of influenza vaccines to be ...
... for patients in ICU by adhering to simple techniques ... infections. ICUs can become thoroughly aseptic by ensuring a ... catheters. A detailed report was made by experts on ... report are published in New England Journal of Medicine. ...
... surgery for his broken leg. Schwarzenegger broke his right femur ... surgery took place three days later and doctors used screws ... ,It is possible that the governor will attend ... ,Orthopaedic surgeon Kevin Ehrhart said: "He is ...
... few nonjudgmental counseling sessions can prompt women to both ... according to a new study//. ,Prenatal alcohol exposure ... developmental disabilities in the United States. This CDC study ... of an alcohol-exposed pregnancy. ,“A lot of ...
... the reason why the common parasite Toxoplasma,// does not ... others seriously ill. , ,Toxoplasma is a genus ... can also be passed on by many other warm-blooded ... which in normal circumstances is not harmful, but can ...
Cached Medicine News:Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 2Health News:Counseling Helps Young Women Cut Drinking, Improve Contraception Use 3
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
Medicine Products: